TY - JOUR AU - Dodson, R. M. PY - 2013 DA - 2013// TI - Intrahepatic cholangiocarcinoma: management options and emerging therapies JO - J Am Coll Surg VL - 217 UR - https://doi.org/10.1016/j.jamcollsurg.2013.05.021 DO - 10.1016/j.jamcollsurg.2013.05.021 ID - Dodson2013 ER - TY - JOUR AU - Razumilava, N. AU - Gores, G. J. PY - 2014 DA - 2014// TI - Cholangiocarcinoma JO - Lancet VL - 383 UR - https://doi.org/10.1016/S0140-6736(13)61903-0 DO - 10.1016/S0140-6736(13)61903-0 ID - Razumilava2014 ER - TY - JOUR AU - Welzel, T. M. PY - 2007 DA - 2007// TI - Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study JO - Clin Gastroenterol Hepatol VL - 5 UR - https://doi.org/10.1016/j.cgh.2007.05.020 DO - 10.1016/j.cgh.2007.05.020 ID - Welzel2007 ER - TY - JOUR AU - Zhou, Y. M. PY - 2008 DA - 2008// TI - Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China JO - World J Gastroenterol VL - 14 UR - https://doi.org/10.3748/wjg.14.632 DO - 10.3748/wjg.14.632 ID - Zhou2008 ER - TY - JOUR AU - Banales, J. M. PY - 2016 DA - 2016// TI - Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) JO - Nat Rev Gastroenterol Hepatol VL - 13 UR - https://doi.org/10.1038/nrgastro.2016.51 DO - 10.1038/nrgastro.2016.51 ID - Banales2016 ER - TY - JOUR AU - Weber, S. M. PY - 2015 DA - 2015// TI - Intrahepatic cholangiocarcinoma: expert consensus statement JO - HPB (Oxford) VL - 17 UR - https://doi.org/10.1111/hpb.12441 DO - 10.1111/hpb.12441 ID - Weber2015 ER - TY - JOUR AU - Vesely, M. D. PY - 2011 DA - 2011// TI - Natural innate and adaptive immunity to cancer JO - Annu Rev Immunol VL - 29 UR - https://doi.org/10.1146/annurev-immunol-031210-101324 DO - 10.1146/annurev-immunol-031210-101324 ID - Vesely2011 ER - TY - JOUR AU - Hanahan, D. AU - Weinberg, R. A. PY - 2011 DA - 2011// TI - Hallmarks of cancer: the next generation JO - Cell VL - 144 UR - https://doi.org/10.1016/j.cell.2011.02.013 DO - 10.1016/j.cell.2011.02.013 ID - Hanahan2011 ER - TY - JOUR AU - Smyth, M. J. PY - 2016 DA - 2016// TI - Combination cancer immunotherapies tailored to the tumour microenvironment JO - Nat Rev Clin Oncol VL - 13 UR - https://doi.org/10.1038/nrclinonc.2015.209 DO - 10.1038/nrclinonc.2015.209 ID - Smyth2016 ER - TY - JOUR AU - Jing, C. Y. PY - 2019 DA - 2019// TI - HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1 JO - J Immunother Cancer VL - 7 UR - https://doi.org/10.1186/s40425-019-0554-8 DO - 10.1186/s40425-019-0554-8 ID - Jing2019 ER - TY - JOUR AU - Gajewski, T. F. AU - Schreiber, H. AU - Fu, Y. X. PY - 2013 DA - 2013// TI - Innate and adaptive immune cells in the tumor microenvironment JO - Nat Immunol VL - 14 UR - https://doi.org/10.1038/ni.2703 DO - 10.1038/ni.2703 ID - Gajewski2013 ER - TY - JOUR AU - Fabris, L. PY - 2019 DA - 2019// TI - The tumour microenvironment and immune milieu of cholangiocarcinoma JO - Liver Int VL - 39 UR - https://doi.org/10.1111/liv.14098 DO - 10.1111/liv.14098 ID - Fabris2019 ER - TY - JOUR AU - Vigano, L. PY - 2019 DA - 2019// TI - Tumor-infiltrating lymphocytes and macrophages in intrahepatic cholangiocellular carcinoma. Impact on prognosis after complete surgery JO - J Gastrointest Surg VL - 23 UR - https://doi.org/10.1007/s11605-019-04111-5 DO - 10.1007/s11605-019-04111-5 ID - Vigano2019 ER - TY - JOUR AU - Atanasov, G. PY - 2017 DA - 2017// TI - Tumor necrosis and infiltrating macrophages predict survival after curative resection for cholangiocarcinoma JO - Oncoimmunology VL - 6 UR - https://doi.org/10.1080/2162402X.2017.1331806 DO - 10.1080/2162402X.2017.1331806 ID - Atanasov2017 ER - TY - JOUR AU - Oishi, K. PY - 2015 DA - 2015// TI - Macrophage density and macrophage colony-stimulating factor expression predict the postoperative prognosis in patients with intrahepatic cholangiocarcinoma JO - Surg Today VL - 45 UR - https://doi.org/10.1007/s00595-014-0989-y DO - 10.1007/s00595-014-0989-y ID - Oishi2015 ER - TY - JOUR AU - Santabarbara, G. PY - 2016 DA - 2016// TI - Novel immunotherapy in the treatment of advanced non-small cell lung cancer JO - Expert Rev Clin Pharmacol VL - 9 UR - https://doi.org/10.1080/17512433.2016.1236681 DO - 10.1080/17512433.2016.1236681 ID - Santabarbara2016 ER - TY - JOUR AU - Ma, J. PY - 2019 DA - 2019// TI - PD1(Hi) CD8(+) T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma JO - J Immunother Cancer VL - 7 UR - https://doi.org/10.1186/s40425-019-0814-7 DO - 10.1186/s40425-019-0814-7 ID - Ma2019 ER - TY - JOUR AU - Gordon, S. R. PY - 2017 DA - 2017// TI - PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity JO - Nature VL - 545 UR - https://doi.org/10.1038/nature22396 DO - 10.1038/nature22396 ID - Gordon2017 ER - TY - JOUR AU - Gani, F. PY - 2016 DA - 2016// TI - Program death 1 immune checkpoint and tumor microenvironment: implications for patients with intrahepatic cholangiocarcinoma JO - Ann Surg Oncol VL - 23 UR - https://doi.org/10.1245/s10434-016-5101-y DO - 10.1245/s10434-016-5101-y ID - Gani2016 ER - TY - JOUR AU - Sui, M. PY - 2019 DA - 2019// TI - Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade JO - J Immunother Cancer VL - 7 UR - https://doi.org/10.1186/s40425-019-0596-y DO - 10.1186/s40425-019-0596-y ID - Sui2019 ER - TY - JOUR AU - Liu, L. Z. PY - 2016 DA - 2016// TI - Protein tyrosine phosphatase PTP4A1 promotes proliferation and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma via the PI3K/AKT pathway JO - Oncotarget VL - 7 UR - https://doi.org/10.18632/oncotarget.12116 DO - 10.18632/oncotarget.12116 ID - Liu2016 ER - TY - JOUR AU - Liu, L. Z. PY - 2018 DA - 2018// TI - CK7/CK19 index: a potential prognostic factor for postoperative intrahepatic cholangiocarcinoma patients JO - J Surg Oncol VL - 117 UR - https://doi.org/10.1002/jso.25027 DO - 10.1002/jso.25027 ID - Liu2018 ER - TY - JOUR AU - Gao, Q. PY - 2009 DA - 2009// TI - Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-08-1608 DO - 10.1158/1078-0432.CCR-08-1608 ID - Gao2009 ER - TY - JOUR AU - Yang, L. X. PY - 2015 DA - 2015// TI - Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition JO - Hepatology VL - 62 UR - https://doi.org/10.1002/hep.28149 DO - 10.1002/hep.28149 ID - Yang2015 ER - TY - JOUR AU - Gorris, M. A. J. PY - 2018 DA - 2018// TI - Eight-color multiplex immunohistochemistry for simultaneous detection of multiple immune checkpoint molecules within the tumor microenvironment JO - J Immunol VL - 200 UR - https://doi.org/10.4049/jimmunol.1701262 DO - 10.4049/jimmunol.1701262 ID - Gorris2018 ER - TY - JOUR AU - Soares, K. C. PY - 2015 DA - 2015// TI - PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors JO - J Immunother VL - 38 UR - https://doi.org/10.1097/CJI.0000000000000062 DO - 10.1097/CJI.0000000000000062 ID - Soares2015 ER - TY - JOUR AU - Tan, D. AU - Sheng, L. AU - Yi, Q. H. PY - 2018 DA - 2018// TI - Correlation of PD-1/PD-L1 polymorphisms and expressions with clinicopathologic features and prognosis of ovarian cancer JO - Cancer Biomark VL - 21 UR - https://doi.org/10.3233/CBM-170357 DO - 10.3233/CBM-170357 ID - Tan2018 ER - TY - JOUR AU - Zheng, B. H. PY - 2017 DA - 2017// TI - A new preoperative prognostic system combining CRP and CA199 for patients with intrahepatic cholangiocarcinoma JO - Clin Transl Gastroenterol VL - 8 UR - https://doi.org/10.1038/ctg.2017.45 DO - 10.1038/ctg.2017.45 ID - Zheng2017 ER - TY - JOUR AU - Ma, K. PY - 2017 DA - 2017// TI - PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma JO - Oncol Lett VL - 14 UR - https://doi.org/10.3892/ol.2017.6105 DO - 10.3892/ol.2017.6105 ID - Ma2017 ER - TY - JOUR AU - Jung, H. I. PY - 2017 DA - 2017// TI - Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma JO - Cancer Res Treat VL - 49 UR - https://doi.org/10.4143/crt.2016.066 DO - 10.4143/crt.2016.066 ID - Jung2017 ER - TY - JOUR AU - Ying, L. PY - 2017 DA - 2017// TI - Understanding immune phenotypes in human gastric disease tissues by multiplexed immunohistochemistry JO - J Transl Med VL - 15 UR - https://doi.org/10.1186/s12967-017-1311-8 DO - 10.1186/s12967-017-1311-8 ID - Ying2017 ER - TY - JOUR AU - Saito, H. PY - 2018 DA - 2018// TI - Highly activated PD-1/PD-L1 pathway in gastric cancer with PD-L1 expression JO - Anticancer Res VL - 38 ID - Saito2018 ER - TY - JOUR AU - Shen, T. PY - 2017 DA - 2017// TI - Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic cancer JO - Sci Rep VL - 7 UR - https://doi.org/10.1038/s41598-017-08479-9 DO - 10.1038/s41598-017-08479-9 ID - Shen2017 ER - TY - JOUR AU - Muenst, S. PY - 2013 DA - 2013// TI - The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer JO - Breast Cancer Res Treat VL - 139 UR - https://doi.org/10.1007/s10549-013-2581-3 DO - 10.1007/s10549-013-2581-3 ID - Muenst2013 ER - TY - JOUR AU - Kansy, B. A. PY - 2017 DA - 2017// TI - PD-1 Status in CD8(+) T cells associates with survival and anti-PD-1 therapeutic outcomes in head and neck cancer JO - Cancer Res VL - 77 UR - https://doi.org/10.1158/0008-5472.CAN-16-3167 DO - 10.1158/0008-5472.CAN-16-3167 ID - Kansy2017 ER - TY - JOUR AU - Thommen, D. S. PY - 2018 DA - 2018// TI - A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade JO - Nat Med VL - 24 UR - https://doi.org/10.1038/s41591-018-0057-z DO - 10.1038/s41591-018-0057-z ID - Thommen2018 ER - TY - JOUR AU - Liu, F. PY - 2018 DA - 2018// TI - Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma JO - Bull Cancer VL - 105 UR - https://doi.org/10.1016/j.bulcan.2018.01.018 DO - 10.1016/j.bulcan.2018.01.018 ID - Liu2018 ER - TY - JOUR AU - Liu, X. PY - 2019 DA - 2019// TI - Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade JO - J Immunother Cancer VL - 7 UR - https://doi.org/10.1186/s40425-019-0692-z DO - 10.1186/s40425-019-0692-z ID - Liu2019 ER - TY - JOUR AU - Liu, C. Q. PY - 2018 DA - 2018// TI - Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma JO - Br J Cancer VL - 119 UR - https://doi.org/10.1038/s41416-018-0144-4 DO - 10.1038/s41416-018-0144-4 ID - Liu2018 ER - TY - JOUR AU - Jiang, C. PY - 2017 DA - 2017// TI - Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages JO - Immunobiology VL - 222 UR - https://doi.org/10.1016/j.imbio.2016.12.002 DO - 10.1016/j.imbio.2016.12.002 ID - Jiang2017 ER - TY - JOUR AU - Cao, L. PY - 2019 DA - 2019// TI - M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer JO - Cancer Manag Res VL - 11 UR - https://doi.org/10.2147/CMAR.S199832 DO - 10.2147/CMAR.S199832 ID - Cao2019 ER - TY - JOUR AU - Hartley, G. P. PY - 2018 DA - 2018// TI - Programmed cell death ligand 1 (PD-L1) signaling regulates macrophage proliferation and activation JO - Cancer Immunol Res VL - 6 UR - https://doi.org/10.1158/2326-6066.CIR-17-0537 DO - 10.1158/2326-6066.CIR-17-0537 ID - Hartley2018 ER - TY - JOUR AU - Pardoll, D. M. PY - 2012 DA - 2012// TI - The blockade of immune checkpoints in cancer immunotherapy JO - Nat Rev Cancer VL - 12 UR - https://doi.org/10.1038/nrc3239 DO - 10.1038/nrc3239 ID - Pardoll2012 ER - TY - JOUR AU - Xiong, H. PY - 2019 DA - 2019// TI - Anti-PD-L1 treatment results in functional remodeling of the macrophage compartment JO - Cancer Res VL - 79 UR - https://doi.org/10.1158/0008-5472.CAN-18-3208 DO - 10.1158/0008-5472.CAN-18-3208 ID - Xiong2019 ER -